1,321 results match your criteria Journal of medical economics[Journal]


Psychometric validation of Anti-Clot Treatment Scale and Treatment Satisfaction Questionnaire for Medication version II in Japanese patients with atrial fibrillation.

J Med Econ 2019 Apr 17. Epub 2019 Apr 17.

i Modus Outcomes Ltd , Letchworth Garden City , UK.

Aims: The Anti-Clot Treatment Scale (ACTS) and Treatment Satisfaction Questionnaire for Medication version II (TSQM-II) are validated treatment satisfaction patient-reported outcome (PRO) instruments. The ACTS includes two domains: Burdens and Benefits; the TSQM-II includes four: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Japanese-language versions of the ACTS and TSQM-II have been developed and linguistically validated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1609003DOI Listing
April 2019
2 Reads

Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.

J Med Econ 2019 Apr 15. Epub 2019 Apr 15.

b The University of Texas at Austin, College of Pharmacy, Health Outcomes Division , United States.

Objectives: To examine suboptimal response (SR) in attention deficit hyperactivity disorder (ADHD) among pediatric patients in the Texas Medicaid program receiving osmotic-release oral system methylphenidate (OROS-MPH) or lisdexamfetamine (LDX) and apply an SR prediction model to identify patients most likely to experience an SR to either OROS-MPH or LDX therapies.

Methods: A retrospective cohort study was conducted using Texas Medicaid claims data of ADHD children and adolescents (6 to 17 years of age) initiating OROS-MPH or LDX. Primary SR endpoints were drug discontinuation, switching, and augmentation 12-months post ADHD drug initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1606814DOI Listing
April 2019
2 Reads

Tofacitinib in the treatment of moderate to severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.

J Med Econ 2019 Apr 13. Epub 2019 Apr 13.

h Pfizer Inc , Groton , CT , USA.

Aims: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis investigated the cost-effectiveness of the second-line treatment with tofacitinib, compared with adalimumab, both plus methotrexate (MTX), in patients with moderate to severe RA and an inadequate response to the first-line MTX, from a Taiwan National Health Insurance Administration perspective.

Materials And Methods: A patient-level simulation model was used to project lifetime costs and quality-adjusted life-years (QALYs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1606813DOI Listing

Treatment patterns and predictors of costs among patients with migraine: evidence from the United States Medical Expenditure Panel Survey.

J Med Econ 2019 Apr 12. Epub 2019 Apr 12.

a Eli Lilly and Company , Indianapolis , IN , USA.

Aim: Within a treated migraine population, to evaluate if the subgroup meeting criteria for high disease-specific total costs is significantly different than the subgroup with medium and/or low-costs, and to identify the associated risk factors.

Methods: Data from the Household Component of Medical Expenditure Panel Survey (MEPS-HC, 2008-2012), a nationally representative survey of noninstitutionalized civilians in USA, were analyzed. Key inclusion criteria were migraine diagnosis (ICD-9 code: 346. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1607358DOI Listing

Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.

J Med Econ 2019 Apr 10. Epub 2019 Apr 10.

f Creativ-Ceutical , London , United Kingdom.

Aims: Non-vitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) are used to prevent stroke in patients with atrial fibrillation (AF). This paper aimed to evaluate the clinical efficacy and safety of NOACs when compared to VKAs by calculating the number needed to treat (NNT) at 2 years using incidence rates and hazard ratios (HRs) derived from a meta-analysis of studies conducted in real-world settings.

Materials And Methods: HRs were sourced from a published systematic literature review and a meta-analysis of real-world evidence on the use of NOACs versus VKAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1606001DOI Listing
April 2019
2 Reads

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.

J Med Econ 2019 Apr 10. Epub 2019 Apr 10.

e Department of Internal Medicine V , Innsbruck University Hospital , Innsbruck , Austria , and Oncotyrol, Center for Personalized Cancer Medicine , Innsbruck , Austria.

Aim: The approved indication for denosumab (120 mg) was expanded in 2018 to include skeletal-related event (SRE) prevention in patients with multiple myeloma (MM). Therefore, we conducted a cost-effectiveness analysis comparing denosumab with zoledronic acid (ZA) for SRE prevention in patients with MM from the national healthcare system perspective in a representative sample of European countries: Austria, Belgium, Greece, and Italy.

Methods: The XGEVA global economic model for patients with MM was used to calculate incremental cost-effectiveness ratios (ICERs) for denosumab versus ZA over a lifetime horizon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1606002DOI Listing
April 2019
3 Reads

Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.

J Med Econ 2019 Apr 3. Epub 2019 Apr 3.

c Department of Health Economics and Outcome Research , Sanofi , Shanghai , China.

Aims: To conduct a lifetime cost-effectiveness analysis (CEA) of rasburicase compared with standard of care (SOC) for tumor lysis syndrome (TLS) in children with hematologic malignancies from the Chinese healthcare system perspective.

Materials And Methods: The CEA was performed using a decision tree model with a lifetime horizon. The model explores the cost-effectiveness of rasburicase verses SOC for both preventing TLS and treating established TLS among pediatric patients with acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and non-Hodgkin's lymphoma (NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1603155DOI Listing
April 2019
2 Reads

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.

J Med Econ 2019 Apr 3. Epub 2019 Apr 3.

e Duke Clinical Research Institute , NC , USA.

Objective: To assess long-term healthcare costs related to ischemic stroke and systemic embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial fibrillation (NVAF) treated with non-vitamin K antagonist oral anticoagulants (NOACs).

Material And Methods: Optum's Clinformatics Data Mart database from 1/2009-12/2016 was analyzed. Adult patients with ≥1 stroke/SE hospitalization (index date) were matched 1:1 to patients without stroke/SE (random index date), based on propensity scores. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1603156DOI Listing
April 2019
4 Reads

Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.

J Med Econ 2019 Mar 27:1-6. Epub 2019 Mar 27.

e United BioSource Corporation , Montreal , Canada.

Objectives: There is a lack of data in Panama on the potential differences in total healthcare professional (HCP) time between routine administrations of short-acting erythropoietin simulating agents (ESAs) (i.e. epoetin alfa) and continuous erythropoietin receptor activator (CERA) (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1600527DOI Listing
March 2019
1 Read

Influencing factors of disability among the elderly in China, 2003-2016: application of Bayesian quantile regression.

J Med Econ 2019 Mar 26:1-7. Epub 2019 Mar 26.

c School of Mathematics and Statistics , Chongqing Technology and Business University , Chongqing , PR China.

Background: More and more disabled elderly need long-term care as China becomes an aging society. In 2016, there were 220 million people over the age of 60, and nearly 10 million completely disabled elderly people who cannot complete Activities of Daily Living (ADLs). Therefore, the topic of influencing factors for disability among the elderly in China has attracted close attention from researchers, most of which use the traditional empirical methods, such as Ordinary Least Squares (OLS) and logistic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1600525DOI Listing

Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings.

J Med Econ 2019 Mar 27. Epub 2019 Mar 27.

c Hunan Key Laboratory of Tumor Modeling and Individualized Medicine , Changsha , China.

Objectives: To describe the clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer (mCRPC) in Chinese patients.

Methods: This retrospective study identified a group of patients with newly developed mCRPC from 2012 to 2016 to extract information from their medical and billing records in two tertiary care hospitals. Descriptive statistical methods were used to summarize patient clinical characteristics, treatment pattern, and monthly medical costs. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1600524DOI Listing
March 2019
4 Reads

Comparative financing analysis and political economy of noncommunicable diseases.

J Med Econ 2019 Mar 27:1-6. Epub 2019 Mar 27.

j Insurance and Health Management at the Fox School of Business , Temple University , Philadelphia , PA , USA.

The pandemic of chronic non-communicable diseases (NCDs) poses substantial challenges to the health financing sustainability in high-income and low/middle income countries (LMICs). The aim of this review is to identify the bottle neck inefficiencies in NCDs attributable spending and propose sustainable health financing solutions. The World Health Organization (WHO) introduced the "best buy" concept to scale up the core intervention package against NCDs targeted for LMICs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1600523DOI Listing
March 2019
1 Read

Reoperations in intramedullary fixation of pertrochanteric hip fractures.

J Med Econ 2019 Mar 26:1-7. Epub 2019 Mar 26.

d Medical Affairs, DePuy Synthes Orthopaedics , West Chester , PA , USA.

Objective: This study evaluated the frequency of reoperation within 1 year of initial intramedullary fixation for patients with pertrochanteric hip fracture and compared 1-year healthcare resource utilization and cost burden for patients with and without reoperation.

Methods: This is a retrospective evaluation of medical claims from the US Centers for Medicare and Medicaid Standard Analytic File. Patients aged ≥65 years who underwent fixation with an intramedullary implant for a pertrochanteric fracture between 2013 and 2015 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1600526DOI Listing
March 2019
2 Reads

Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries.

J Med Econ 2019 Mar 21:1-8. Epub 2019 Mar 21.

g Gustave Roussy, Université Paris-Saclay, Service de Biostatistique et d'Epidémiologie , Villejuif , France.

Aims: Overall survival (OS) of patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is extremely poor. New therapeutic options emerge but need to establish their economic value. The objective was to describe the direct and related costs of R/M SCCHN in France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1594837DOI Listing
March 2019
3 Reads

Bias-corrected estimates of reduction of post-surgery length of stay and corresponding cost savings through the widespread national implementation of fast-tracking after liver transplantation: a quasi-experimental study.

J Med Econ 2019 Mar 6:1-7. Epub 2019 Mar 6.

b Department of Transplant , Mayo Clinic Florida , Jacksonville , FL , USA.

Background: Fast-tracking is an approach adopted by Mayo Clinic in Florida's (MCF) liver transplant (LT) program, which consists of early tracheal extubation and transfer of patients to surgical ward, eliminating a stay in the intensive care unit in select patients. Since adopting this approach in 2002, MCF has successfully fast-tracked 54.3% of patients undergoing LT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1592179DOI Listing

Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England.

J Med Econ 2019 Mar 29:1-7. Epub 2019 Mar 29.

d University Hospitals Birmingham , Birmingham , UK.

Aims: To examine healthcare resource utilization associated with refractory myasthenia gravis (MG) in England.

Materials And Methods: This was a retrospective cohort study of linked data from the Clinical Practice Research Datalink and the Hospital Episode Statistics database collected between 1997 and 2016. Included patients were ≥18 years of age at the index MG diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1592180DOI Listing

The importance of accounting for the uncertainty around the preference-based health-related quality-of-life measures value sets: a systematic review.

J Med Econ 2019 Mar 6:1-13. Epub 2019 Mar 6.

a Faculty of Agricultural and Food Science , American University of Beirut , Beirut , Lebanon.

Preference-based measures of health-related quality-of-life including, but not limited to, the EQ-5D, HUI2 and the SF-6D have been increasingly used in calculations of quality-adjusted life years for cost effectiveness analyses. However, the uncertainty around the measures' value sets is commonly ignored in economic evaluation. There are several types of uncertainties, including methodological, structural, and parameter uncertainties, with the latter being the focus of this review paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1592178DOI Listing

Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.

J Med Econ 2019 Mar 6:1-10. Epub 2019 Mar 6.

c Sterling Simulation , Kissimmee , FL , USA.

Aims: To model implementation of a new treatment pathway leveraging long-acting antibiotics (LAs) for treatment of acute bacterial skin and skin structure infections (ABSSSIs) in a hospital emergency department (ED) with an observation unit, and to quantify health resource utilization and economic outcomes versus standard care (intravenous vancomycin).

Materials And Methods: Discrete-event simulation was used to model implementation of the LA treatment pathway in the ED versus standard care from the US Medicare perspective. Model inputs were derived from published sources to simulate a real-world hospital ED with an observation unit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1591423DOI Listing
March 2019
1 Read

Hospital costs associated with intraoperative hypotension among non-cardiac surgical patients in the US: a simulation model.

J Med Econ 2019 Mar 6:1-7. Epub 2019 Mar 6.

e Cleveland Clinic , Cleveland , OH , USA.

Objective: Recent studies indicate intraoperative hypotension, common in non-cardiac surgical patients, is associated with myocardial injury, acute kidney injury, and mortality. This study extends on these findings by quantifying the association between intraoperative hypotension and hospital expenditures in the US.

Methods: Monte Carlo simulations (10,000 trial per simulation) based on current epidemiological and cost outcomes literature were developed for both acute kidney injury (AKI) and myocardial injury in non-cardiac surgery (MINS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1591147DOI Listing
March 2019
2 Reads

Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.

J Med Econ 2019 Mar 6:1-9. Epub 2019 Mar 6.

c Hormone Responsive Cancers Program, University of Maryland Greenebaum Comprehensive Cancer Center and Baltimore VA Medical Center , Baltimore , MD , USA.

Aims: Medicare patients with metastatic or surgically unresectable urothelial carcinoma (mUC) often receive platinum-based chemotherapy as first line of therapy (LOT), but invariably progress, requiring additional LOTs and healthcare resource use (HCRU). To better understand the evolving mUC treatment landscape, the economic burden of chemotherapy-based mUC treatments among US Medicare patients was estimated.

Methods: Newly diagnosed Medicare patients with mUC were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1591424DOI Listing
March 2019
3 Reads

Migraine burden and costs in France: a nationwide claims database analysis of triptan users.

J Med Econ 2019 Mar 5:1-9. Epub 2019 Mar 5.

b Cemka , Bourg-la-Reine , France.

Objectives: To estimate the burden of migraine in the population of French patients identified as specific migraine acute treatment users compared to a control group.

Methods: A cross-sectional retrospective analysis was performed on the Echantillon Généraliste des Bénéficiaires claims database, a 1/97 random sample of the French public insurance database. A representative sample of all adults with at least one delivery of triptans, ergot derivatives or acetylsalicylic acid/metoclopramide (all drugs with a specific label in migraine acute treatment - SMAT) in 2014 was selected with a control group matched on age, gender and geographic region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1590841DOI Listing

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).

J Med Econ 2019 Mar 5:1-13. Epub 2019 Mar 5.

g Department of Oncology, University of Alberta, Cross Cancer Institute , Edmonton , Canada.

Aim: To assess the cost-effectiveness in Canada of atezolizumab compared with docetaxel or nivolumab for the treatment of advanced NSCLC after first-line platinum-doublet chemotherapy.

Materials And Methods: A three-state partitioned-survival model was developed. Clinical inputs were obtained from the phase III OAK trial comparing atezolizumab with docetaxel in patients with advanced NSCLC who progressed after first-line platinum-doublet chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1590842DOI Listing
March 2019
2 Reads

The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina.

J Med Econ 2019 Mar 5:1-7. Epub 2019 Mar 5.

c Cornerstone Research Group Inc , Burlington , Ontario , Canada.

Objective: Osteoporosis is under-diagnosed and under-treated worldwide. Information on the burden of osteoporosis in Latin American countries is limited. This study aimed to estimate the economic burden of osteoporosis in adults aged 50-89 years in Brazil, Mexico, Colombia, and Argentina. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1590843DOI Listing
March 2019
1 Read

Correction.

J Med Econ 2019 Mar 1. Epub 2019 Mar 1.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1584497DOI Listing
March 2019
3 Reads

Cost-effectiveness analyses using real-world data: an overview of the literature.

J Med Econ 2019 Feb 28:1-9. Epub 2019 Feb 28.

e Aix-Marseille University , Marseille , France.

Objectives: Real-world evidence (RWE) may provide good estimates of absolute event probabilities and costs in patients in actual clinical practice, but their use in decision-analytic models poses many challenges. A literature review based on a systematic search was conducted to summarize the limitations of using RWE in decision-analytic modeling reported in the literature, but also to identify existing recommendations about real-world modeling.

Methods: A literature search was performed on Medline and Embase databases, as well as relevant websites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1588737DOI Listing
February 2019

Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.

J Med Econ 2019 Feb 27:1-12. Epub 2019 Feb 27.

h Otsuka Pharmaceutical Development & Commercialization , Rockville , MD , USA.

Aims: The overall cost and health-related quality of life (HRQoL) associated with current treatments for chronic kidney disease (CKD)-related anemia are not well characterized. A systematic literature review (SLR) was conducted on the costs and HRQoL associated with current treatments for CKD-related anemia among dialysis-dependent (DD) patients.

Materials And Methods: The authors searched the Cochrane Library, MEDLINE, EMBASE, NHS EED, and NHS HTA for English-language publications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1588738DOI Listing
February 2019
3 Reads

Psychiatric inpatient cost of care before and after admission at a residential subacute step-up/step-down mental health facility.

J Med Econ 2019 May 15;22(5):491-498. Epub 2019 Mar 15.

a Centre for Indigenous Health Equity Research and School of Health, Medical and Applied Sciences, Psychology and Public Health Department , CQUniversity , Brisbane , Australia.

Background: Residential step-up/step-down services provide transitional care and reintegration into the community for individuals experiencing episodes of subacute mental illness. This study aims to examine psychiatric inpatient admissions, length of stay, and per capita cost of care following the establishment of a step-up/step-down Prevention And Recovery Care (PARC) facility in regional Australia.

Methods: This was a pragmatic before and after study set within a participatory action research methodology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1588126DOI Listing

Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.

J Med Econ 2019 Feb 26:1-9. Epub 2019 Feb 26.

a Departmen of Oncology , Xiangya Hospital, Central South University , Changsha , PR China.

Objective: To estimate the cost-effectiveness of utidelone plus capecitabine therapy compared to capecitabine alone in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes treatment in the Chinese context and provide a reference for the marketing of utidelone in China.

Methods: A Markov model was developed based on the NCT02253459 clinical trial to simulate the clinical course of patients with metastatic breast cancer who had received taxanes and anthracycline therapy. The quality-adjusted life years (QALYs) and Incremental Cost Effectiveness Ratio (ICER) were then analyzed to evaluate the benefits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1588125DOI Listing
February 2019
1 Read

Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis.

J Med Econ 2019 Mar 21:1-7. Epub 2019 Mar 21.

c Stony Brook University , Stony Brook , NY , USA.

Background: Heart failure (HF) is a common, serious disease in the US and Europe. Patients with HF often require treatment for fluid overload, resulting in costly inpatient visits; however, limited evidence exists on the costs of alternative treatments. This study performed a cost-analysis of ultrafiltration (UF) vs diuretic therapy (DIUR-T) for patients with HF from the hospital perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1584109DOI Listing

Health state utilities associated with treatment options for acute myeloid leukemia (AML).

J Med Econ 2019 Feb 18:1-10. Epub 2019 Feb 18.

f Jazz Pharmaceuticals, Inc , Palo Alto , CA , USA.

Aims: Acute myeloid leukemia (AML) treatment typically involves remission induction chemotherapy followed by consolidation chemotherapy. New treatments for AML have recently been introduced, including a chemotherapy formulation called CPX-351, which is administered via less time-intensive IV infusion than the standard "7 + 3" continuous infusion regimen of cytarabine plus an anthracycline. The purpose of this study was to estimate utilities that could be used in economic modeling of AML treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1584108DOI Listing
February 2019
3 Reads

The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.

J Med Econ 2019 May 4;22(5):478-487. Epub 2019 Mar 4.

b Department of Clinical Epidemiology and Biostatistics (CEB) , McMaster University , Hamilton , Ontario , Canada.

Background: Both public and private insurers provide drug coverage in Canada. All payers are under pressure to contain costs. It has recently been proposed that private plans leverage the public health technology assessment (HTA) evaluation process in their decision-making. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582535DOI Listing

The whole is greater than the sum of its parts: the importance of integrated, universal, and equitable healthcare coverage.

J Med Econ 2019 May 8;22(5):488-490. Epub 2019 Mar 8.

a Pharmacoepidemiology-Pharmacovigilance, Pharmacy Programme Department of Life and Health Sciences School of Sciences and Engineering , University of Nicosia , Nicosia , Cyprus.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582536DOI Listing

CAR T-cells: costs, comparisons, and commentary.

J Med Econ 2019 Feb 12:1-3. Epub 2019 Feb 12.

b Canadian Cancer Trials Group , Kingston , Ontario , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582059DOI Listing
February 2019
1 Read

Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance.

J Med Econ 2019 May 4;22(5):471-477. Epub 2019 Mar 4.

e Harvard Business School , Boston , MA , USA.

Objectives: To determine how overall cost of anticoagulation therapy for warfarin compares with that of Novel Oral Anticoagulants (NOACs). Also, to demonstrate a scientific, comprehensive, and an analytical approach to estimate direct costs involved in monitoring and management of anticoagulation therapy for outpatients in an academic primary care clinic setting, post-initiation of therapy.

Methods: A population-based cross-sectional study was conducted in conjunction with observations of patient care processes between August 2014 and January 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582058DOI Listing
May 2019
1 Read

Does the critical illness insurance reduce patients' financial burden and benefit the poor more: a comprehensive evaluation in rural area of China.

J Med Econ 2019 May 8;22(5):455-463. Epub 2019 Mar 8.

a School of Medicine and Health Management , Huazhong University of Science and Technology , Wuhan , China.

Background: Critical illness insurance (CII) is one kind of health insurance that is gradually gaining attention worldwide. China implemented CII in 2012 to decrease patients' out-of-pocket (OOP) medical payments. The aims of this study were to determine if the project had positive impacts on relieving financial burden and improving health equity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1581620DOI Listing
May 2019
1 Read

Economic impact of introducing TYRX amongst patients with heart failure and reduced ejection fraction undergoing implanted cardiac device procedures: a retrospective model based cost analysis.

J Med Econ 2019 May 20;22(5):464-470. Epub 2019 Feb 20.

a School of Biomedical Engineering and Imaging Sciences , Rayne Institute, Kings College London , London , UK.

Background And Aims: Infection is a serious and expensive complication of Cardiac Implantable Electronic Device (CIED) procedures. A retrospective based cost analysis was performed to estimate Trust level savings of using the TYRX antibacterial envelope as a primary prevention measure against infection in a tertiary referral centre in South London, UK.

Methods: A retrospective cohort of heart failure patients with reduced ejection fraction undergoing Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) procedures were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1581621DOI Listing

The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.

J Med Econ 2019 May 4;22(5):447-454. Epub 2019 Mar 4.

b Eli Lilly and Company , Indianapolis , IN , USA.

Aims: Examine healthcare costs across chronic kidney disease (CKD) stages for US patients with type 2 diabetes (T2D).

Materials And Methods: IQVIA Real World Data Adjudicated Claims linked electronic medical records and insurance claims from January 1, 2012 through March 31, 2017 were used for this retrospective study. Adults diagnosed with T2D and comorbid CKD were included. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1581208DOI Listing
May 2019
3 Reads

Cost-impact of cardiac magnetic resonance imaging with Fast-SENC compared to SPECT in the diagnosis of coronary artery disease in the U.S.

J Med Econ 2019 May 15;22(5):430-438. Epub 2019 Mar 15.

a Avalon Health Economics , Morristown , NJ , USA.

Aims: The purpose of this study is to assess the economic cost differences and the associated treatment resource changes between the developing coronary artery disease (CAD) diagnostic tool fast strain-encoded cardiac imaging (Fast-SENC) and the current commonly used stress test single-photon emission computed tomography (SPECT).

Materials And Methods: A "payer perspective" model was created first, consisting of long-term and short-term components that used a hypothetical cohort of patients of average age (60.8 years) presenting with chest pain and suspected CAD to assess cost-impact. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1580713DOI Listing
May 2019
1 Read

Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.

J Med Econ 2019 May 5;22(5):439-446. Epub 2019 Mar 5.

f Sun Yat-sen University , College Town , Guangzhou , China.

Objectives: This study aimed to analyze (1) the cost-effectiveness of olanzapine orally disintegrating tablet (ODT) compared to olanzapine standard oral tablet (SOT) and (2) the cost-effectiveness of olanzapine-SOT compared to aripiprazole-SOT for patients with schizophrenia in China.

Methods: A microsimulation model was adapted from a healthcare payers' perspective. The model ran over a 1-year time horizon, using quarterly cycles. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1580714DOI Listing
May 2019
6 Reads

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

J Med Econ 2019 May 1;22(5):414-420. Epub 2019 Mar 1.

a IQVIA , Falls Church , VA , USA.

Introduction: The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC) patients with rearrangement of the anaplastic lymphoma kinase (ALK) gene. The objective of this study was to measure the impact of copay assistance on patient cost sharing and treatment patterns in patients prescribed oral ALK inhibitors (ALKi's). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1580200DOI Listing
May 2019
2 Reads

The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records.

J Med Econ 2019 May 4;22(5):421-429. Epub 2019 Mar 4.

a Mallinckrodt Pharmaceuticals, Inc , Bedminster , NJ , USA.

Objectives: Hepatorenal Syndrome (HRS) is characterized by renal failure in patients with advanced chronic liver disease (CLD) and is the leading cause of hospitalizations in CLD. This study examines the clinical and economic burden, outcomes, and unmet need of HRS treatment in US hospitals.

Method: A retrospective cohort study was conducted based on a large electronic health records database (Cerner HealthFacts) with records for hospitalized HRS patients from January 2009-June 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1580201DOI Listing
May 2019
4 Reads

A Monte Carlo simulation estimating US hospital cost reductions associated with hypotension control in septic ICU patients.

J Med Econ 2019 Apr 19;22(4):383-389. Epub 2019 Feb 19.

e Cleveland Clinic , Cleveland , OH , USA.

Objective: This economic analysis extends upon a recent epidemiological study to estimate the association between hypotension control and hospital costs for septic patients in US intensive care units (ICUs).

Methods: A Monte Carlo simulation decision analytic model was developed that accounted for the probability of complications-acute kidney injury and mortality-in septic ICU patients and the cost of each health outcome from the hospital perspective. Probabilities of complications were calculated based on observational data from 110 US hospitals for septic ICU patients (n = 8,782) with various levels of hypotension exposure as measured by mean arterial pressure (MAP, units: mmHg). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1576695DOI Listing
April 2019
2 Reads

A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilization (HCRU) in schizophrenia.

J Med Econ 2019 May 5;22(5):403-413. Epub 2019 Mar 5.

e HEOR Medical Affairs, Lundbeck A/S , Valby , Denmark.

Aims: There have been no systematic literature reviews (SLRs) evaluating the identified association between outcomes (e.g. clinical, functional, adherence, societal burden) and Quality-of-Life (QoL) or Healthcare Resource Utilization (HCRU) in schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1576694DOI Listing
May 2019
1 Read

The economic burden of depression among adults with rheumatoid arthritis in the United States.

J Med Econ 2019 Apr 5;22(4):372-378. Epub 2019 Feb 5.

a Janssen Global Services , Horsham , PA , USA.

Aims: Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to assess healthcare utilization, expenditures, and work productivity among patients with RA with or without depression. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1572015DOI Listing
April 2019
22 Reads

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.

J Med Econ 2019 Apr 4;22(4):336-343. Epub 2019 Feb 4.

a Department of Endocrinology & Metabolism , Peking University People's Hospital , Beijing , PR China.

Background And Objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the disease burden of diabetes and its complications is very heavy. Because a new diabetes treatment strategy for diabetes should consider its cost-effectiveness, compared with an existing treatment, this study aimed to examine the cost-effectiveness between dapagliflozin and metformin treatment in China.

Methods: The Cardiff Diabetes Model (CDM) was used to estimate cost effectiveness and macro- and micro-vascular outcomes of dapagliflozin vs metformin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1570220DOI Listing
April 2019
1 Read

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada.

J Med Econ 2019 Apr 4;22(4):390-401. Epub 2019 Feb 4.

e Goeree Consulting Ltd, Hamilton , ON , Canada.

Objectives: To estimate the cost-utility of two trabecular micro-bypass stents (TBS) implantation vs standard of care (SOC) in patients with mild-to-moderate open-angle glaucoma (OAG) in the Canadian healthcare setting.

Methods: The deterioration in visual field (VF) defect over a 15-year time horizon was tracked using a Markov model with Hodapp-Parrish-Anderson stages of glaucoma (mild, moderate, advanced, severe/blind) and death as health states. Meta-analyses of randomized clinical trials were conducted to estimate the pooled reduction in intraocular pressure (IOP) and medication use due to TBS and SOC. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1572013DOI Listing
April 2019
13 Reads

Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.

J Med Econ 2019 Jan 19:1-13. Epub 2019 Jan 19.

a Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences , Naresuan University , Phitsanulok , Thailand.

Aims: Non-adherence is associated with poor clinical outcomes among patients with asthma. While cost-effectiveness analysis (CEA) is increasingly used to inform value assessment of the interventions, most do not take into account adherence in the analyses. This study aims to: (1) Understand the extent of studies considering adherence as part of the economic analyses, and (2) summarize the methods of incorporating adherence in the economic models. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1572014DOI Listing
January 2019
10 Reads

The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.

J Med Econ 2019 Apr 12;22(4):350-358. Epub 2019 Feb 12.

b Bristol-Myers Squibb , Lawrenceville , NJ 08648 , USA.

Aims: To estimate real world healthcare costs and resource utilization of rheumatoid arthritis (RA) patients associated with targeted disease modifying anti-rheumatic drugs (tDMARD) switching in general and switching to abatacept specifically.

Materials And Methods: RA patients initiating a tDMARD were identified in IMS PharMetrics Plus health insurance claims data (2010-2016), and outcomes measured included monthly healthcare costs per patient (all-cause, RA-related) and resource utilization (inpatient stays, outpatient visits, emergency department [ED] visits). Generalized linear models were used to assess (i) average monthly costs per patient associated with tDMARD switching, and (ii) among switchers only, costs of switching to abatacept vs tumor necrosis factor inhibitors (TNFi) or other non-TNFi. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1571498DOI Listing
April 2019
15 Reads